TRexBio
TRexBio develops medicines designed to regulate the immune system for autoimmune and inflammatory diseases.
TRexBio (Ticker: TRXB US) develops medicines that regulate the immune system for autoimmune and inflammatory diseases. TRexBio is a clinical-stage biotechnology company headquartered in South San Francisco, California. Its Deep Biology platform is designed to identify drivers of immune-system disruption and inform drug discovery and development. The platform supports a wholly owned medicine pipeline and collaborations with pharmaceutical companies.
The scheduled listing date on Nasdaq was October 9, 2026. The proposed offering comprises 8,300,000 shares at an indicative price range of $14.00–16.00 per share. At the indicative range midpoint, the base offering would represent $124.50 million in gross proceeds, excluding any unexercised over-allotment.
J.P. Morgan, Evercore, Cantor and Stifel are bookrunners. J.P. Morgan is also the stabilization agent and bill-and-deliver bank.
Prepared with IPOX® AI assistance. Information may contain errors.
